Efficacy and Biological Correlates of Response in a Phase 2 Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

We present a phase 2, single-arm study evaluating 800 mg daily venetoclax, a highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL-2) inhibitor in patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or unfit for intensive chemotherapy. Responses were evaluate...

詳細記述

保存先:
書誌詳細
出版年:Cancer Discov
主要な著者: Konopleva, Marina, Pollyea, Daniel A., Potluri, Jalaja, Chyla, Brenda, Hogdal, Leah, Busman, Todd, McKeegan, Evelyn, Salem, Ahmed Hamed, Zhu, Ming, Ricker, Justin L., Blum, William, DiNardo, Courtney D., Kadia, Tapan, Dunbar, Martin, Kirby, Rachel, Falotico, Nancy, Leverson, Joel, Humerickhouse, Rod, Mabry, Mack, Stone, Richard, Kantarjian, Hagop, Letai, Anthony
フォーマット: Artigo
言語:Inglês
出版事項: 2016
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5436271/
https://ncbi.nlm.nih.gov/pubmed/27520294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0313
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料